NASDAQ:ANAC

(ANAC) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume1.81 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Anacor Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. Its lead product development candidate is crisaborole topical ointment, approximately 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the treatment of mild-to-moderate atopic dermatitis and psoriasis. Its product, KERYDIN (tavaborole) topical solution, approximately 5%, is an oxaborole antifungal approved by the United States Food and Drug Administration (FDA) for the topical treatment of onychomycosis of the toenails. It also has a pipeline of other internally discovered topical and systemic boron-based compounds in early-stages of research and development, which include AN3365. Its compound, AN5568 (SCYX-7158), is licensed to Drugs for Neglected Diseases initiative (DNDi) for the treatment of human African trypanosomiasis.
(ANAC) logo

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:ANAC
CUSIP03242010
Phone+1-650-5437500
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Headlines

Announcement of Drawings - Yahoo Finance UK
February 22, 2021 |  uk.finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

0.62 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Receive ANAC News and Ratings via Email

Sign-up to receive the latest news and ratings for ANAC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











(ANAC) (NASDAQ:ANAC) Frequently Asked Questions

What stocks does MarketBeat like better than (ANAC)?

Wall Street analysts have given (ANAC) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but (ANAC) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were (ANAC)'s earnings last quarter?

(ANAC) (NASDAQ:ANAC) posted its quarterly earnings data on Tuesday, May, 10th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.01. The biopharmaceutical company had revenue of $17.54 million for the quarter, compared to analyst estimates of $19.53 million. The company's revenue for the quarter was up 14.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.30) earnings per share.
View (ANAC)'s earnings history
.

Who are some of (ANAC)'s key competitors?

What other stocks do shareholders of (ANAC) own?

What is (ANAC)'s stock symbol?

(ANAC) trades on the NASDAQ under the ticker symbol "ANAC."

What is (ANAC)'s official website?

The official website for (ANAC) is www.anacor.com.

Where are (ANAC)'s headquarters?

(ANAC) is headquartered at 1020 E Meadow Cir, PALO ALTO, CA 94303-4230, United States.

How can I contact (ANAC)?

(ANAC)'s mailing address is 1020 E Meadow Cir, PALO ALTO, CA 94303-4230, United States. The biopharmaceutical company can be reached via phone at +1-650-5437500.


This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.